To assess the effects of oral nimodipine on the mortality rate and neurologic outcome of patients with an acute ischemic stroke.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Double-blind, placebo-controlled, multicenter trial involving 164 patients.
One hundred sixty-four patients were randomly allocated to receive either nimodipine tablets (30 mg qid.) or identical placebo tablets for 28 days. Treatment was always started <= 48 hours after the acute event.
|Type||Measure||Time Frame||Safety Issue|
|Primary||The Mathew Scale (modified by Gelmers et al). Mortality rate and neurologic outcome after 28 days.|